<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371982</url>
  </required_header>
  <id_info>
    <org_study_id>INSERM-237-6900, Paris 6-069</org_study_id>
    <nct_id>NCT00371982</nct_id>
  </id_info>
  <brief_title>Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <brief_summary>
    <textblock>
      1. whether the intake of n-3 PUFA has additional effects on insulin sensitivity and
           adiposity (total fat mass and adipocyte morphology and function) in T2D women.

        2. n-3 PUFA supplementation might influence inflammatory genes expression in the adipose
           tissue of T2D patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thus, the present study was designed to evaluate the effects of n-3 PUFAs dietary
      supplementation on lipid and glucose homeostasis and to address the impact of this treatment
      on adiposity and adipose tissue gene expression in T2D women.A total of 27 T2D women (BMI
      27-35kg/m², age 40-60 y) were randomly allocated to two months of 3 g/day of either fish oil
      (1.8 g n-3 PUFA) or placebo (paraffin oil), in a double-blind parallel design.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2002</start_date>
  <completion_date>April 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of 2 month treatment on:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>adiposity (total fat mass, adipocyte morphology), atherogenic markers and insulin sensitivity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>the underlying mechanisms of the observed results and tried to define new targets of fish oil metabolic effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and the impact of fish oil on systemic inflammatory markers and adipose tissue inflammatory genes.</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish oil (Maxepa)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetic postmenopausal women

          2. glycaemia of 7.87-14.0 mmol/l, HbA1c of 7 to 10.5%

          3. plasma triglycerides between 1.72-4.6 mmol/l,

          4. aged between 40 -60,

          5. BMI: 27-40 kg/m2

          6. able to swallow tablets

        Exclusion Criteria:

          1. patients with abnormal renal, hepatic and thyroid functions as determined by physical
             examination, blood cell count and standard blood biochemical profile

          2. patients with gastrointestinal disorders

          3. patients treated with thiazolidinediones or insulin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salwa W Rizkalla, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM (National institution of Health and Medical Research)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard Slama, MD, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Public Assistance-Paris Hospitals (AP-HP), University Paris 6</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Diabetes-Hotel Dieu Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2006</study_first_submitted>
  <study_first_submitted_qc>September 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2006</study_first_posted>
  <last_update_submitted>September 1, 2006</last_update_submitted>
  <last_update_submitted_qc>September 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2006</last_update_posted>
  <keyword>Fish oil</keyword>
  <keyword>Type 2 diabetic women</keyword>
  <keyword>adiposity</keyword>
  <keyword>adipose tissue inflammation</keyword>
  <keyword>PAI-1</keyword>
  <keyword>Insulin sensitivity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

